Global Ganja Report

As the cannabis industry is embraced by corporate power and finance capital, the patenting of strains, products and applications is an increasing concern. But the international patchwork of legality makes for a confusing environment. Illegality has served as a paradoxical break on privatizing of varieties. Growers and advocates are devising means to protect the genetic commons in the new cannabis order.

With the legal cannabis market increasingly dominated by "Big Bud," more Canadians are turning to homegrown—both for reasons of economy and an ethic of self-sufficiency. And they are fighting in the courts and the public squares for their right to do so—challenging both the federal limit on plants per household and efforts by two provinces to ban homegrown outright. So far, they are winning. 

In Washington state, glitches in the "seed-to-sale" tracking system nearly paralyzed the cannabis industry statewide last month, costing retailers hundreds of thousands of dollars and forcing temporary lay-offs of employees. Similar headlines have been seen from across the country's legalized states—pointing to a persistent issue.

The arrival of 7-10 as a special day to celebrate extracts and concentrates marks the growing embrace of "dabbing" by the cannabis community. But the laws governing such products and especially their production vary from state to state. And the real risks continue to garner grim headlines that cast the cannabis industry in a very poor light.

Finally settling a question that has vexed the Arizona medical marijuana program since it was launched nearly a decade ago, the state's highest court ruled that the program does indeed cover concentrates and extracts. The decision is a victory for patients who use edibles, tinctures or hashish.

A bill that would legalize "recreational" cannabis is moving forward in Hawaii's state legislature. It would build on the dispensary system established by the state's medical marijuana program to bring about a regulated adult-use market.

CBD-infused foods and beverages are the target of a crackdown in New York City, as well as Maine and Ohio. A budding business of cannabinoid-enhanced concoctions and libations is feeling a sudden pinch. But some media coverage is failing to make clear that what is at issue here is the FDA's failure to keep pace with federal law—not any inherent risks of cannabidiol.

In Arizona, the statehouse and supreme court are in a race to clarify whether hashish is to be included in the Grand Canyon State's medical marijuana program. The question also has implications for the status of extracts and edibles.